Evidence map›Paper›PMID 33411055›Full record

ArticleNanoscale research letters2021

Targeted Single-Walled Carbon Nanotubes for Photothermal Therapy Combined with Immune Checkpoint Inhibition for the Treatment of Metastatic Breast Cancer.

Patrick McKernan, Needa A Virani, Gabriela N F Faria, Clément G Karch, Ricardo Prada Silvy, Daniel E Resasco, Linda F Thompson, Roger G Harrison

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanoscale research letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 66 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Comprehensive comparison of theranostic nanoparticles in breast cancer.American journal of clinical and experimental immunology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Patrick McKernanDepartment of Neurology, Neurosurgery, and Radiation Oncology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
Needa A ViraniDepartment of Radiation Oncology, Brigham and Women's Hospital, Harvard Medical School, and Dana-Farber Cancer Institute, Boston, MA, USA.
Gabriela N F FariaSchool of Chemical, Biological and Materials Engineering, University of Oklahoma, Norman, OK, USA.
Clément G KarchSchool of Biomedical Engineering, University of Oklahoma, Norman, OK, USA.
Ricardo Prada SilvySchool of Chemical, Biological and Materials Engineering, University of Oklahoma, Norman, OK, USA.
Daniel E ResascoSchool of Chemical, Biological and Materials Engineering, University of Oklahoma, Norman, OK, USA.
Linda F ThompsonArthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
Roger G HarrisonSchool of Chemical, Biological and Materials Engineering, University of Oklahoma, Norman, OK, USA. rharrison@ou.edu.ORCID http://orcid.org/0000-0003-2401-627X
University of Oklahoma · USBrigham and Women's Hospital · USOklahoma Medical Research Foundation · USOklahoma State University Oklahoma City · USUniversity of Oklahoma Health Sciences Center · US

Funding

Oklahoma Center for the Advancement of Science and Technology HR14-136
6 · The paper itself

Abstract

The greatest contributors to cancer mortality are metastasis and the consequences of its treatment. Here, we present a novel treatment of metastatic breast cancer that combines photothermal therapy with targeted single-walled carbon nanotubes (SWCNTs) and immunostimulation with a checkpoint inhibitor. We find that the selective near-infrared photothermal ablation of primary orthotopic EMT6 breast tumors in syngeneic BALB/cJ mice using an annexin A5 (ANXA5) functionalized SWCNT bioconjugate synergistically enhances an anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4)-dependent abscopal response, resulting in an increased survival (55%) at 100 days after tumor inoculation. In comparison, there was no survival at 100 days for either photothermal therapy by itself or immunostimulation by itself. Prior to photothermal therapy, the SWCNT-ANXA5 bioconjugate was administered systemically at a relatively low dose of 1.2 mg/kg, where it then accumulated in tumor vasculature via ANXA5-dependent binding. During photothermal therapy, the average maximum temperature in the tumor reached 54 °C (duration 175 s). The mechanism of prolonged survival resulting from combinatorial photothermal ablation and immune stimulation was evaluated by flow cytometric quantification of splenic antitumoral immune effector cells and serum cytokine quantification.

Indexed as

Annexin A5Breast cancerImmune checkpoint inhibitorPhotothermal therapySingle-walled carbon nanotubes

Identifiers

PMID33411055
PMCPMC7790975
OpenAlexW3120911161

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.